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Abstract
Background
Bloom syndrome is an autosomal recessive disorder characterized by extraordinary cancer incidence early in life and an average life expectancy of ~27 years.
Premature stop codons in BLM, which encodes a DNA helicase that functions in
DNA double-strand-break repair, make up the vast majority of Bloom syndrome
mutations, with only 13 single amino acid changes identified in the syndrome.
Sequencing projects have identified nearly one hundred single nucleotide variants
in BLM that cause amino acid changes of uncertain significance.
Methods and Results
Here, in addition to identifying five BLM variants incapable of complementing
certain defects of Bloom syndrome cells, making them candidates for new
Bloom syndrome causing mutations, we characterize a new class of BLM variants that cause some, but not all, cellular defects of Bloom syndrome. We find
elevated sister-chromatid exchanges, a delayed DNA damage response and inefficient DNA repair. Conversely, hydroxyurea sensitivity and quadriradial chromosome accumulation, both characteristic of Bloom syndrome cells, are absent.
These intermediate variants affect sites in BLM that function in ATP hydrolysis
and in contacting double-stranded DNA.
Conclusion
Allele frequency and cellular defects suggest candidates for new Bloom syndrome causing mutations, and intermediate BLM variants that are hypomorphic which, instead of causing Bloom syndrome, may increase a person’s risk
for cancer or possibly other Bloom-syndrome-associated disorders, such as
type-2 diabetes.

Introduction
Bloom syndrome (MIM 210900 for BLM) is a rare chromosome breakage disorder characterized by short stature
and an extraordinary predisposition to a broad range of
cancers, often multiple, early in life (German and Passarge
1989; German and Ellis 1998). Other symptoms that can
be present in persons with Bloom syndrome include sunsensitive skin with telangiectatic and hyper- and hypopigmented areas, immunodeficiency, subfertility in females
and infertility in males, and type 2 diabetes mellitus
106

(Bloom 1954; German and Passarge 1989; German and
Ellis 1998; Ellis et al. 2008).
The gene defective in persons with Bloom syndrome –
the tumor suppressor gene BLM – encodes a 30 to 50
DNA helicase that belongs to the evolutionarily conserved
RecQ helicase family (Ellis et al. 1995; Bennett and Keck
2004). The helicase core of BLM spans amino acid residues 658 to 1197 and consists of the DNA-dependent
ATPase (DEAH) domain with seven conserved helicase
motifs, and the RecQ-C-terminal (RQC) domain with
Zn-binding (Zn) and winged-helix (WH) subdomains
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(Hickson 2003; Bennett and Keck 2004). C-terminal of
the RQC domain is the conserved Helicase and RNase D
C-terminal (HRDC) domain, which plays a role in DNA
binding and is thought to regulate helicase activity
(Huber et al. 2006; Kim and Choi 2010). The best understood roles for BLM are in the repair of DNA double
strand breaks (DSBs) by homologous recombination
(HR) where – in a complex with topoisomerase Topo IIIa
and Rmi1/Rmi2 – BLM dissolves double Holliday junctions (dHJ) into noncrossover products (Hickson 2003).
BLM/Topo IIIa/Rmi1/Rmi2 has also been implicated in
the processing of the ends of DSBs into single-strand 30
overhangs for the strand invasion step of HR and in the
control of HR levels by reversing strand invasion events
(Bachrati et al. 2006; Daley et al. 2014; Sturzenegger et al.
2014). As a result, cells that lack functional BLM exhibit
elevated levels of mitotic recombination, chromatid
breaks, increased crossover formation between sister chromatids (~10-fold higher in cells from persons with Bloom
syndrome), and signs of illegitimate interchromosomal
recombination events suggested by the presence of
quadriradial chromosomes (Chaganti et al. 1974; Groden
et al. 1990; Lonn et al. 1990; Groden and German 1992).
Consistent with the role of BLM in maintaining genome
integrity, Bloom syndrome cells are sensitive to genotoxic
agents, including hydroxyurea (HU), which causes replication stress by depleting the nucleotide pool, and camptothecin (CPT), a natural product that interferes with
replication and transcription by trapping topoisomerase I
on nicked DNA. The elevated level of mitotic recombination between homologous chromosomes is thought be a
major contributor to the extraordinary cancer predisposition in Bloom syndrome as it can lead to the loss of
heterozygosity (LOH) at loci carrying tumor-suppressor
genes (Chester et al. 1998; Traverso et al. 2003).
BLM is transcribed as a 97.93 kb pre-messenger RNA,
with 21 exons coding for a 1417 amino acid protein. In
the majority of persons with Bloom syndrome the BLM
gene is inactivated by small insertion/deletion mutations
or nonsense mutations that lead to a premature stop
codon upstream or within exons 7–18, which code for
the helicase core of BLM. The most common Bloom syndrome mutation is a 6 bp deletion/7 bp insertion in exon
9 (6-BP DEL/7-BP INS, rs113993962:ATCTGA>TAGATTC) (Ellis et al. 1994, 1998; Li et al. 1998; Straughen
et al. 1998; German et al. 2007). This frameshift indel
mutation changes the amino acids encoded by codons
736–739 before causing a premature stop in codon 740
(p.Tyr736fsX4). This mutation, also referred to as blmASH,
occurs with a frequency of ~0.01 in the Ashkenazi Jewish
population (Li et al. 1998). In addition to mutations
causing premature chain termination, 13 missense mutations in the ATPase and RQC domains of the BLM

helicase core have been identified in persons with Bloom
syndrome (Ellis et al. 1995; Foucault et al. 1997; Barakat
et al. 2000; German et al. 2007). Seven of the missense
mutations alter amino acid residues in the ATPase
domain (Q672R, I841T, C878R, G891E, C901Y, G952V,
H963Y) whereas the six missense mutations in the RQC
domain mostly affect the highly conserved cysteine residues involved in Zn coordination (C1036F, C1055S,
C1055R, C1055G, D1064V, C1066Y) (Fig. 1A). The lack
of differences in the expression of Bloom syndrome
between individuals with these missense mutations, either
in the homozygous or compound heterozygous state, and
individuals with early chain-terminating mutations suggests that they all inactivate BLM (Ellis et al. 1995).
There is some evidence that heterozygosity for BLM
mutations leads to increased colorectal cancer risk in
humans and mice (Goss et al. 2002; Gruber et al. 2002),
and causes increased sensitivity to DNA-damaging agents
in a diploid yeast model (Mirzaei and Schmidt 2012).
However, it is unclear if besides fully inactivating mutations that cause Bloom syndrome other naturally occurring BLM mutations cause more subtle functional defects
that might be new cancer risk factors in otherwise healthy
individuals. To address this question we used a yeast
model to screen coding single nucleotide polymorphisms
(SNPs) in the human BLM gene for those that impair
BLM function as estimated by the hypersensitivity of cells
to HU (Mirzaei and Schmidt 2012). This yeast model
expressed a chimera of the N-terminal 648 residues of
Sgs1 (the BLM-related RecQ helicase in Saccharomyces
cerevisiae) and the C-terminal 800 residues of human
BLM to which 41 nonsynonymous SNPs from the Short
Genetic Variations database (dbSNP) map. We ranked
these 41 coding SNPs and two additional SNPs reported
in the literature (German et al. 2007) based on their
probability to impair BLM function using PolyPhen
(Ramensky et al. 2002) and evaluated the 22 SNPs predicted to be ‘probably’ or ‘possibly’ damaging (PolyPhen
score >1.5) for their effect on BLM function in vivo
(Mirzaei and Schmidt 2012). The screen identified eight
SNPs that impaired BLM function, all of which had a
PolyPhen score >2 (rs761589072:C>T, P690L; rs28406486:
G>C, R717T; rs55880859:C>T, R791C; rs148394770:T>C,
W803R; rs145029382:A>G, Y811C; rs2227935:C>T,
P868L; rs150475674, G972V:G>T; rs139773499:G>A,
G1120R) (Table 1) (Fig. 1A). Interestingly, this screen
suggested that in addition to rare null alleles that had not
yet been associated with Bloom syndrome more common
BLM alleles may also be functionally impaired. The higher
frequency of these alleles in the human population (e.g.
rs2227935:C>T, P868L; 5.13%) suggests that they are
insufficient for full-scale Bloom syndrome, but their lower
functional activity may lead to an increased cancer risk
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later in life or an increased risk for developing other
symptoms of Bloom syndrome, such as type 2 diabetes
mellitus or fertility problems. Here, we have quantified
functional defects of cells expressing these new BLM alleles, with an emphasis on the first three hypomorphic
BLM
allele
candidates
(rs2227935,
rs55880859,
rs139773499) by assessing chromosomal abnormalities,
their ability to respond to genotoxic agents and their ability to repair DSBs.

Materials and Methods
Cell lines, plasmids, and transfection
GM08505 is an SV40-transformed skin fibroblast cell line
established from a patient with Bloom syndrome (Ellis

108

Figure 1. Ability of BLM variants to
complement the hydroxyurea sensitivity of the
BLM-deficient cell line GM08505. (A) Map of
human BLM with conserved helicase motifs IVI, the RecQ-C-terminal (RQC) domain
consisting of Zn-binding and winged helix
(WH) subdomains, and the Helicase- and
RNaseD-C-terminal (HRDC) domain. Sites of
known Bloom syndrome causing missense
mutations are indicated above the map and
locations of BLM variants analyzed in this
study are indicated below the map. (B)
GM08505 cells, which are homozygous for the
blmASH mutation and do not express fulllength BLM (lane 2), express stably transfected
BLM variants (lanes 4–11) at similar levels as
wildtype BLM (lane 3). Endogenous BLM
expression in the normal fibroblast cell line
GM00637 is shown lane 1. (C–D) Cells were
exposed to increasing concentrations of
hydroxyurea (0.1–0.5 mmol/L) for 48 h and
survivors (colonies with ~50 or more cells)
were counted after up to 4 weeks of growth
in hydroxyurea-free media. Three
independently generated stable cell lines were
analyzed for BLM and every BLM variant.
Mean  SD is shown.

et al. 1995) and was obtained from Coriell Cell Repository.
GM00637 is an SV40-transformed skin fibroblast cells line
from an unaffected individual (Coriell Cell Repository).
Cells were grown in minimal essential medium (Corning,
Tewksbury, MA) supplemented with 10% FBS and
2 mmol/L glutamine at 37°C in the presence of 5% CO2.
GM08505 cells were plated 24 h before transfections at
approximately 2 9 104 per cm2. BLM cDNA cloned into
pcDNA3 vector and mutated at stated sites using sitedirected mutagenesis was transfected using Polyfect (Qiagen, Valencia, CA). Stable clones were selected in the
presence of G418 (750 lg/mL). Clones were maintained
in the presence of G418 (350 lg/mL). BLM cDNA in
pcDNA3 was a kind gift from Dr. Ian Hickson, University of Copenhagen. Cell lines expressing the BLM variants evaluated in this study are listed in Table 2.
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Table 1. BLM gene variants evaluated in this study.
Prediction of functional impact
Nucleotide change
c.2069C>T
c.2150G>C
c.2371C>T
c.2407T>C
c.2432A>G
c.2603C>T
c.2915G>T
c.3358G>A

1

Amino acid change
p.Pro690Leu
p.Arg717Thr
p.Arg791Cys
p.Trp803Arg
p.Tyr811Cys
p.Pro868Leu
p.Gly972Val
p.Gly1120Arg

2

dbSNP ID

Allele frequency

rs761589072
rs28406486
rs55880859
rs148394770
rs145029382
rs2227935
rs367543034
rs139773499

n.a.
n.a.
0.0002
n.a.
n.a.
0.0513
n.a.
n.a.

3

PolyPhen4

PolyPhen25

2.724
2.008
2.495
3.757
2.616
2.724
2.397
2.172

1
0.985
0.981
1
1
0.729
1
0.999

SIFT6
0
0.15
0.01
0
0
0.02
0
0

FIS7
4.875
0.85
2.81
4.965
4.955
2.395
2.295
3.285

1

GenBank RefSeq: NM_000057.3.
GenBank RefSeq: NP_000048.1.
3
Minor allele frequencies from dbSNP (http://www.ncbi.nlm.nih.gov/SNP/).
4
Prediction using PolyPhen (http://genetics.bwh.harvard.edu/pph/index.html): red, ‘probably damaging’.
5
Prediction using PolyPhen-2 (http://genetics.bwh.harvard.edu/pph/): red, probably damaging; yellow, possibly damaging.
6
Prediction using SIFT (http://sift.jcvi.org/): red, damaging; green, tolerated.
7
Predicted Functional Impact Score via Mutation Assessor (http://mutationassessor.org/); red, high functional impact; yellow, medium functional
impact; green, low functional impact.
2

Subcellular fractionation and western
blotting
Nuclear extracts were prepared from exponentially growing cells to detect BLM expression. Cells were lysed in
20 mmol/L Tris pH 7.4, 10 mmol/L KCl, 1 lmol/L
EDTA, 0.2% NP40, 50% glycerol, 0.6 mmol/L b-mercaptoethanol, 1 mmol/L PMSF, and protease inhibitor cocktail (Pierce, Rockford, IL), followed by nuclear extraction
in 20 mmol/L Tris pH 7.4, 10 mmol/L KCl, 0.4 mol/L
NaCl, 1 mmol/L EDTA, 50% glycerol, 0.6 mmol/L BME,
1 mmol/L PMSF, and protease inhibitor cocktail (Pierce).
Mouse monoclonal antibody BLM-F5 (SCBT, Dallas, TX)
was used to detect BLM and a monoclonal tubulin antibody (Abcam, Cambridge, MA) was used as a loading
control.

tion microscope with a Plan-Apochromat 100x/1.40 Oil
DIC M27 objective Zeiss, Thornwood, NY. For each cell
line, a minimum of 1500 chromosomes were analyzed.
The mean  SD is reported.

Clonogenic survival assay
Cells were seeded at a density of 500 cells/well for colony
formation. On the next day, either fresh medium containing HU (0.1, 0.2, 0.3, 0.4, or 0.5 mmol/L) or drug-free
medium was added. The medium was removed after 48 h
and cells were washed with PBS before colonies were
allowed to grow in fresh complete growth medium for up
to 4 weeks. Colonies were fixed in 3:1 (vol/vol) methanol-acetic acid and stained with 0.01% crystal violet.
Colonies with more than 50 cells were scored as survivors.

Differential sister-chromatid staining
Sister chromatid exchanges (SCEs) were quantified using
protocols described previously (Perry and Wolff 1974;
Bayani and Squire 2001; Campos et al. 2009). Briefly, cells
were cultured for two cell cycles in growth medium supplemented with BrdU Labeling Reagent (Life Technologies, Carlsbad, CA) and metaphase arrest was induced by
the addition of 0.1 lg/mL colcemid for 1 h. Chromosome
spreads were prepared after hypotonic treatment with
75 mmol/L KCl and fixation with 3:1 (vol/vol) methanolacetic acid. Metaphase spreads were differentially stained
using Hoechst 33258 (75 lg/mL; Life Technologies) and
Giemsa (3.5%; Life Technologies). Images of intact metaphases were acquired on a Zeiss Axiovert 100 deconvolu-

cH2AX accumulation and elimination
Exponentially growing cells were exposed to 1 lmol/L
CPT for 1 h, released into fresh media, and harvested at
various time points (10 min, 20 min, 30 min, 45 min,
1 h, 8 h, 24 h, and 48 h). To detect cH2AX, chromatin
fractions were prepared from nuclear extracts using
0.5 mol/L HCl, 50% glycerol, 100 mmol/L b-mercaptoethanol and then neutralized using NaOH in 40 mmol/
L Tris pH 7.4 with protease inhibitor cocktail (Pierce)
(Rios-Doria et al. 2009). Chromatin fractions were separated on 16% Tricine-SDS polyacrylamide (Schagger
2006) and Western blots were probed with PhosphoDetect Anti-H2AX [pSer139] (Upstate Cell Signalling,
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Table 2. Summary of functional evaluation of BLM alleles.
Chromosome abnormalities1

DNA damage response2

Quadriradials

cH2AX
accumulation

cH2AX
elimination

DNA in
comet tail (%)5

0.27  0.12
1.33  0.16
0.91  0.13
n.d.
0.19  0.09
0.69  012
n.d.
0.13  0.07
n.d.
0.182  0.08


+++
+++
n.d.
+
n.d.
n.d.
+
n.d.
+


+++
+++
n.d.
+++
n.d.
n.d.
+++
n.d.
+++

67  1.1/10  0.3
70  0.7/32  0.9
n.d.
n.d.
n.d.
n.d.
n.d.
63  0.7/19  0.4
n.d.
n.d.

BLM allele

dbSNP ID

Cell line3

HU sensitivity4

SCEs

wildtype
blm-Ash6
blm-P690L
blm-R717L
blm-R791C
blm-W803R
blm-Y811C
blm-P868L
blm-G972V
blm-G1120R

n.a.
rs113993962
rs761589072
rs28406486
rs55880859
rs148394770
rs145029382
rs2227935
rs367543034
rs139773499

KSVS1400
GM08505
KSVS1409
KSVS1405
KSVS1425
KSVS1424
KSVS1416
KSVS1419
KSVS1413
KSVS1410


+++
+++
+++
+/
+++
+++
+/
+++
+/

0.18
1.44
1.35
n.d.
0.74
1.51
n.d.
0.81
n.d.
0.94

 0.05
 0.05
 0.07
 0.04
 0.24
 0.12
 0.11

1

Sister-chromatid exchanges (SCEs) are shown as SCEs per chromosome with standard deviation; quadriradials are shown as number of quadriradial chromosomes per metaphase (46 chromosomes) with standard deviation; n.d., not determined.
2
DNA damage response was assessed by H2AX phosphorylation status; + and +++ denote mild and severe delays in the accumulation or elimination of phosphorylated H2AX after treatment with 1 µmol/L CPT.
3
Cell lines were generated by stable transfection of cell line GM08505 (BLMAsh/Ash) with pcDNA3 containing BLM cDNA, or BLM cDNA with the
indicated nucleotide change. Skin fibroblast cell line GM08505 derived from an individual with Bloom syndrome was obtained from Coriell
Biorepository.
4
+++ more sensitive to HU than wildtype BLM complemented cells at all tested HU concentrations (0.1–0.5 mmol/L); +/ more sensitive than wildtype BLM complemented cells at low HU concentrations, but not at higher HU concentration.
5
DNA double-strand breaks were visualized by neutral comet assay; fraction of DNA (%) in the comet tail was quantified 1/48 h after release from
treatment with 1 µmol/L CPT; n.d. not determined.
6
NM_000057.3(BLM):c.2207_2212delATCTGAinsTAGATTC (p.Tyr736Leufs).

Billerica, MA) and polyclonal histone H3 antibody
(Abcam). Changes in cH2AX levels with respect to histone H3 levels were quantified using ImageJ (Rasband
1997–2014). To inhibit PP2A-mediated dephosphorylation of cH2AX, 25 nmol/L okadaic acid was added to
cells immediately after CPT treatment.

Comet assay
Neutral comet assays were performed according to protocols described earlier (Olive and Banath 2006; Nowsheen et al. 2012). Briefly, replication-dependent DNA
breaks were induced by addition of 1 lmol/L CPT to
cell cultures for 1 h. Cells were harvested immediately
after treatment and after growth in drug-free media for
1, 24, and 48 h. Single cell suspensions in 1% low melt
agarose were plated on slides, lysed using neutral lysis
buffer and electrophoresed for 30 min. Slides were fixed
in 70% ethanol and stained with SYBR Gold (Life Technologies). Images were acquired on an UltraVIEW VoX
Life Cell Imager (Perkin Elmer, Waltham, MA) equipped
with a Zeiss Axiovert 200 and a 20x/0.8 M27 Plan-Apochromat objective using Volocity software. At least 50
comets were imaged for three independent cell lines for
a minimum of 150 comets at each time point. The
mean of the tail DNA percentage was calculated using
OpenComet (Gyori et al. 2014).

110

Results
Skin fibroblast cell lines established from persons with
Bloom syndrome (e.g., GM08505) exhibit a spontaneous,
approximately 10-fold increase in the frequency of SCEs
compared to cells from unaffected persons; they also present with quadriradial chromosomes in metaphase
spreads, are hypersensitive to HU, and show a delay in
activating the DNA damage response after exposure to
the topoisomerase poison CPT. To determine the ability
of eight SNPs that cause single amino acid changes in
BLM (Table 1) to complement the cellular defects of
Bloom syndrome cells, the SNPs were introduced into
BLM cDNA in vector pcDNA3 and expressed in cell line
GM08505, in which both BLM alleles are inactivated by
the blmAsh mutation. For each of the eight BLM variants
at least three stable cell lines, expressing each BLM variant
at levels similar to that of wildtype BLM in a skin fibroblast cell line from an unaffected individual (GM00637),
were constructed and analyzed for DNA-damage sensitivity using a clonogenic (survival) assay (Fig. 1). Expression
of wildtype BLM improved survival of Bloom syndrome
cells GM08505 in the presence of HU to that of
GM00637, whereas expression of P690L, R717T, W803R,
Y811C, and G972V caused no improvement (Fig. 1C),
suggesting that they eliminate BLM function. Survival of
GM08505 cells expressing the R791C, P868L and G1120R
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variants, however, was not significantly different from
wildtype BLM (Fig. 1D).
The decreased ability of BLM-deficient cells to dissolve
intermediates of HR as noncrossovers is thought to be a
cause of the increased frequency of exchange of genetic
material between sister chromatids, which can be visualized by differential staining with Hoechst/Giemsa after
two rounds of cell division in the presence of the thymidine analog BrdU (Perry and Wolff 1974) (Fig. 2B, panel
a). We measured a 12-fold increase in the SCE frequency
in GM08505 cells compared to GM00637 (Fig. 2A), consistent with previous findings in cell lines derived from
persons with Bloom syndrome (Ellis et al. 1999). Since
the P690L, R717T, W803R, Y811C, and G972V mutations
caused the same HU hypersensitivity in human cells as
the known Bloom syndrome causing blmAsh mutation
(Fig. 1C), and the same HU hypersensitivity as the helicase-dead blm-K695A mutation in yeast (Mirzaei and Schmidt 2012) we focused the evaluation of chromosome
abnormalities on the R791C, P868L, and G1120R alleles,
and only included two representatives from the group of
null alleles, P690L (Walker A motif) and W803R (conserved aromatic-rich loop). As expected, we found that
expression of wildtype BLM in GM08505 lowered the
SCE frequency to levels seen in normal fibroblasts
whereas expression of variants that exhibited a null phenotype in the HU survival assay had no significant effect
on SCE frequency, remaining 7-fold (P690L) to 8-fold
(W803R) higher than cells expressing wildtype BLM
(Fig. 2A). Expression of variants R791C, P868L, and
G1120R, which suppressed HU hypersensitivity of

GM08505 cells as effectively as wildtype BLM, lowered
SCE frequency of Bloom syndrome cells (P < 0.01)
(Fig. 2A), but levels were still significantly higher (4–5fold, P < 0.01) than in cells expressing wildtype BLM,
indicating reduced BLM activity.
In contrast with genetic exchange between sister chromatids, recombination between homologous chromosomes can give rise to LOH; it can thus be considered
mutagenic and a driver of tumorigenicity in Bloom syndrome. Such recombination events between nonsister
chromatids of homologous chromosomes and, potentially,
nonhomologous chromosomes are captured in metaphase
spreads as quadriradial chromosomes (Fig. 2B, panel d).
As expected, we did not find quadriradials in normal
GM00637 fibroblasts, but observed ~13 for every 10 metaphases in GM08505 cells (Fig. 2C). Quadriradial formation was reduced ~5-fold to fewer than three
quadriradials for every 10 metaphases upon expression of
wildtype BLM. The same reduction was achieved by
expression of R791C, P868L, and G1120R, whereas
quadriradials still formed readily in GM08505 cells
expressing P690L or W803R (Fig. 2C).
In addition to increased recombination events between
sister and nonsister chromatids, cells from Bloom syndrome patients show a delay in the induction of the DNA
damage response after exposure to genotoxic agents, such
as CPT (Rao et al. 2005), which at low concentrations
(≤1 lmol/L) induces replication-specific DSBs (Holm
et al. 1989; Pommier 2006). Phosphorylation of the histone H2A variant H2AX at serine 139 is one of the first
markers of DSB formation in eukaryotic cells (Rogakou
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Figure 2. Chromosomal aberrations in GM08505 cells expressing BLM variants. (A) Analysis of sister-chromatid exchanges (SCEs) by differential
sister-chromatid staining of metaphase chromosomes identifies two groups of BLM variants; variants that cause hypersensitivity to HU (see
Fig. 1C), here represented by P690L and W803R, show SCE levels similar to GM08505, whereas variants that do not cause hypersensitivity to
0.5 mmol/L HU (R791C, P868L, G1120R) (Fig. 1D) had reduced levels of SCEs compared to Bloom syndrome cells, but levels were still higher than
in GM08505 cells expressing wildtype BLM. SCEs per 46 metaphase chromosomes are shown. (B) Types of chromosomal aberrations commonly
observed in Bloom syndrome cells include (a) SCEs, (b) chromatid gaps, (c) segmented chromosomes, and (d) quadriradial chromosomes. (C)
Appearance of quadriradial chromosomes in metaphase spreads of GM08505 cells expressing BLM variants R791C, P868L, and G1120R is
reduced to wildtype levels, whereas expression of P690L or W803R variants caused significantly elevated formation of quadriradial chromosomes.
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et al. 1998). Phosphorylated H2AX, cH2AX, is thought to
recruit and retain DNA damage response and repair factors at DSBs and increase their accessibility to the DSB
site by facilitating chromatin remodeling (Celeste et al.
2002; Fernandez-Capetillo et al. 2002; Stucki et al. 2005;
Tsukuda et al. 2005; Kolas et al. 2007). Results obtained
from an H2AX-S139A mutant suggest that H2AX phosphorylation also plays a role in checkpoint activation
(Rios-Doria et al. 2009). Upon completion of DSB repair,
elimination of cH2AX, either by dephosphorylation or
exchange with H2AX, is needed for cell cycle progression
(Rogakou et al. 1998; Chowdhury et al. 2005; Keogh et al.
2006). To determine the effect of BLM variants on the
induction of the DNA damage response we exposed cells
to 1 lmol/L CPT for 1 h, removed the drug, and assessed
the accumulation of cH2AX every 10 min for 1 h
(Fig. 3). To follow completion of DSB repair and cessation of the DNA damage response we extended this time
course to 48 h to evaluate the kinetics of the elimination
of cellular cH2AX. cH2AX accumulation in Bloom syndrome cells complemented with wildtype BLM peaked
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D

GM08505+BLM

R791C

B

E

GM08505

P868L

C

F

Time after release from CPT (h)
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1 h after CPT removal and then cH2AX levels declined
rapidly, being undetectable by Western blot after 24 h
(Fig. 3A, Fig. S1). In contrast, in Bloom syndrome cells
cH2AX levels did not peak until 32 h after drug removal
and declined only slowly, with most of the H2AX still
phosphorylated after 48 h (Fig. 3B). Bloom syndrome
cells expressing the P690L variant, a representative of the
five alleles that were hypersensitive to HU in human cells
and in yeast, followed the same kinetics of cH2AX accumulation and elimination as Bloom syndrome cells, further supporting the null phenotype of this BLM variant
(Fig. 3C). Interestingly, in Bloom syndrome cells expressing R791C, P868L, or G1120R mutations, cH2AX accumulation reached its peak 1 h after CPT removal as in
cells expressing wildtype BLM, but there was distinctly
less cH2AX, especially at early time points. Even more
noticeable, at the 24-hour time point, when cH2AX was
undetectable in complemented Bloom syndrome cells,
most of the cH2AX was still present in these mutants,
thus resembling the severely delayed elimination of
cH2AX in Bloom syndrome cells (Fig. 3D–F, Fig. S1).

P690L

G1120R

Figure 3. Response of Bloom syndrome cells
(GM08505) expressing BLM variants to
replication-dependent DNA breaks. DNA
breaks were induced by exposure to 1 lmol/L
CPT for 1 h. Accumulation and elimination
cH2AX in comparison to histone H3 was
quantified by Western blot of extracts from
cells collected over a 48 h time course (Fig.
S1). Increasing levels of cH2AX are indicated in
red, and declining levels in blue. Three
independent, stable cell lines were analyzed
for GM08505 cells expressing wildtype BLM
(A) or BLM variants (C–F). Mean  SD is
shown.
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We therefore wanted to test if this impaired elimination of cH2AX in cells with the intermediate phenotype
(Fig. 3D–F) affected the cells’ ability to mount a response
to repeated exposure to a genotoxin. We first tested
Bloom syndrome cells complemented with wildtype BLM.
Cells were exposed to 1 lmol/L CPT for 1 h and then
released into media without CPT, with aliquots being
removed every 10 min for 1 h and again after 8 h since
at this time point cH2AX levels had declined significantly
(Fig. 3A). At this 8 h time point cells were again exposed
to 1 lmol/L CPT for 1 h, released into fresh media, and
aliquots collected at the same time points as in the first
cycle (Fig. 4A). The kinetics of the two cycles of H2AX
accumulation/elimination were nearly indistinguishable,
suggesting that wildtype cells were capable of mounting
proficient responses to repeated insults from CPT. To test
blm-P868L, the intermediate BLM variant with the highest allele frequency in the human population (5.13%), we
exposed cells to a second dose of CPT after 24 h (instead
of 8 h) because only then did we start to see significant
elimination of cH2AX (Fig. 3E). As wildtype cells, blmP868L cells responded equally well to both exposures of
CPT; however, with a marked >16 h delay in cH2AX
elimination in both cycles (Fig. 4B). Despite lower initial
H2AX phosphorylation and severely delayed dephosphorylation compared to wildtype cells, blm-P868L cells
responded significantly better to repeated CPT exposure
than Bloom syndrome cells (Fig. 3 and 4C).

At low concentrations (<50 nmol/L) okadaic acid selectively inhibits the cH2AX phosphatase PP2A (Honkanen
and Golden 2002). Loss of PP2A activity has been shown
to cause cell cycle changes, increased sensitivity to DNA
damaging agents, and delay in DNA repair, probably
enhanced by affecting the activity of other PP2A substrates in addition H2AX, such as ATM, Chk2, and DNAPK (Douglas et al. 2001; Dozier et al. 2004; Goodarzi
et al. 2004; Chowdhury et al. 2005). Bloom syndrome
cells complemented with BLM or blm-P868L survived
treatment with 25 nmol/L okadaic acid with sustained
maximum levels of cH2AX (Fig. S2), whereas Bloom syndrome cells died. To test if the marked delay in cH2AX
accumulation and elimination after CPT removal in cells
expressing P868L corresponded to unrepaired DSBs, we
performed a neutral comet assay (Fig. 5). Cells were
exposed to 1 lmol/L CPT for 1 h and released into fresh
media, with cells being removed for lysis and electrophoresis at the end of the incubation with CPT (0 h)
and then after 1, 24, and 48 h. In wildtype cells, DNA
breaks were significantly reduced over the 48 h time
course, with 23% and 14% of DNA damage remaining
after 24 and 48 h respectively. In blm-P868L cells twice as
much DNA damage (28%, P < 0.0001) was still unrepaired after 48 h, indicating a lag of DNA repair of at
least 24 h. This presents a significant loss in DNA break
repair activity of the P868L variant, but not as great as
that of Bloom syndrome cells where the amount of unre-

Figure 4. DNA-damage response after repeated induction of DNA breaks by camptothecin (CPT). (A) GM08505 + BLM cells were exposed to
1 lmol/L CPT for 1 h, released into drug-free media, and cH2AX levels analyzed by Western blot every 10 min for 1 h and again after 8 h. At
the 8-hour time point cells were exposed to a second round of 1 lmol/L CPT treatment since at this point cH2AX levels in GM08505 + BLM cells
had significantly declined (see Fig. 3A). cH2AX levels were analyzed again every 10 min for 1 h and then after 8 h. (B) Cells expressing variant
P868L were exposed twice to CPT as in (A), but the second exposure to CPT occurred after 24 h since this was the first time point at which a
significant decline in cH2AX was detected in cells expressing the P868L variant (see Fig. 3E). (C) Comparison of cH2AX accumulation in the first
hour after CPT removal. cH2AX levels were quantified by Western blot for GM08505 cells and three independent stable cell lines expressing
wildtype BLM or the P868L variant. Western blots were analyzed using ImageJ (Schneider et al. 2012). Mean  SD is shown.
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Figure 5. Efficiency of repair of replication-dependent DNA double-strand breaks. (A) Neutral comet assay indicates varying levels of doublestrand break repair 24 h after CPT treatment of GM08505 cells expressing no BLM, wildtype BLM, or BLM variant P868L. (B) Tail DNA content
was quantified with OpenComet in 150 comets from GM08505 cells and three independent stable cell lines expressing BLM or BLM variant
P868L. Mean  SD is shown. The asterisks indicates P < 0.001.

paired DNA breaks after 48 h was three times higher
(43%, P < 0.0001) than in wildtype cells.

Discussion
In this study, we have identified variable functional
defects of novel variants of the tumor-suppressor BLM.
Five of the eight variants cause cellular defects that are
indistinguishable from those of Bloom syndrome cells,
indicating that they encode nonfunctional BLM variants
that would cause Bloom syndrome in the homozygous or
compound heterozygous state. The amino acid changes in
these five BLM variants – P690L, R717T, Y811C, W803R,
G972V – cluster along the catalytic cleft between the Nterminal and the C-terminal lobe of the ATPase domain
of the helicase core. Residues that make up the seven conserved helicase motifs of BLM are located at the surface
of this cleft to bind ATP, Mg2+ and single-stranded DNA
and, eventually, to hydrolyze ATP. The null phenotype
exhibited by the five BLM variants can be explained by
the location of the mutated residues in or near these conserved helicase motifs. These new null alleles are the first
to inactivate BLM by mutation of residues in or near
motifs I (P690L), Ia (R717T), VI (G972V), and the conserved aromatic loop (W803R, Y811C), whereas the
known Bloom syndrome-associated amino acid changes
map to motifs 0 (Q672R) and IV (G891E, C901Y) or fall
outside of the conserved motifs (I841T, C878R) (Guo
et al. 2007). The location of the new missense mutations
in the (Walker A) motif I for ATP binding or in other
conserved helicase motifs suggests that the null phenotype
of the new BLM variants is due to loss of ATPase activity.
While it is not surprising that ATPase activity would be
required for BLM’s role in suppressing SCEs by dissolving
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dHJ as noncrossovers, our findings also implicate ATPase
activity in the role of BLM as a transducer of H2AX
phosphorylation in response to replication-dependent
DSBs (Rao et al. 2005), most likely to mediate early
events (e.g., resection, unwinding) at collapsed replication
forks. Resembling the known Bloom syndrome causing
missense mutations, with each having been identified in
only one person (German et al. 2007), the new null variants are very rare in the human population, with allele
frequencies of <0.01 (Sherry et al. 2001, Exome Variant
Server, 2015).
In addition to new null alleles, we identified the first
BLM variant, P868L (rs11852361), that exhibits some, but
not all, defects of Bloom syndrome causing mutations
and does not, based on its relatively high allele frequency,
cause Bloom syndrome. The frequency of P868L in the
human population is 5.13%, ranging from 0.6% in the
Japanese to 12.3–15.3% (15/122 alleles, 1000 Genomes
Project Consortium; 15/98 alleles, CSHL-HAPMAP) in
the population of African descent in the South Western
United States (ASW) (International HapMap, 2003, Thorisson et al. 2005, 1000 Genomes Project Consortium,
2012). Homozygosity for P868L in the ASW population
was 1 in 61 (1/61 genomes, 1000GENOMES) and 1 in 25
(2/49 genomes, CSHL-HAPMAP), with the next highest
frequencies in the Finnish (3/93 genomes) and the British
(2/89 genomes) (International HapMap Consortium
2003, Thorisson et al. 2005, 1000 Genomes Project Consortium 2012). In our study, cells expressing the P868L
variant exhibited a significantly elevated SCE frequency
(Fig. 2A), an aberrant (slow) DNA-damage response, and
inefficient repair of DNA-damage-induced, replicationdependent DSBs (Fig. 3B). On the other hand, blmP868L expressing cells showed similar HU sensitivity and
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frequency of quadriradial chromosomes as cells expressing
wildtype BLM. When mapped onto the recently released
crystal structure of human BLM (Swan et al. 2014),
P868L affects a residue in a loop of unknown function in
the C-terminal lobe of the ATPase domain. This lysinerich loop is not near the catalytic cleft where the null
mutations map, but instead appears to contact doublestranded (ds) DNA bound by the WH domain just before
it is unwound (Fig. 6A). Based on this location we propose that replacing the helix breaker proline with
hydrophobic leucine disrupts the flexibility and
hydrophilicity of the loop, weakening dsDNA binding.
Biochemical analysis of the purified BLM variant will be
necessary to determine if less efficient dsDNA binding, in
and of itself, causes the slower and abnormal DNA break
repair exhibited by the P868L variant, or if it is due to
less efficient ATP hydrolysis since the ATPase activity of
BLM is single-stranded (ss) DNA-dependent.
In addition to P868L we identified two other BLM
variants that fall into this new class of intermediate (hypomorphic) mutations. G1120R is the first BLM missense
mutation from the human population that maps to the
WH domain and impairs BLM function. The WH
domain is conserved structurally, but not at the amino

A

B

Lysine-rich loop
(868PKKPKK873)

acid level. We found that one of the few exceptions is the
first glycine (G1120) in the loop between the second and
third a-helix of the domain (a2–a3 loop), which is conserved in members of the RecQ helicase family from bacteria, to yeast, to humans. It is still unclear how the WH
domain contributes to BLM function since BLM lacking
this domain still possesses helicase activity (Gyimesi et al.
2012). Nonetheless, the loop with G1120 has been shown
to expand in the related human RecQ helicase WRN
upon DNA binding, exposing an arginine for dsDNA
binding (Kitano et al. 2010). Similarly, the corresponding
loop in the recently released crystal structure of human
BLM is near dsDNA (Swan et al. 2014) (Fig. 6 B). We
propose that the G1120R mutation, by removing the
helix-terminating glycine, extends the a2-helix, eliminating or at least reducing the loop structure for dsDNA
binding. Unlike P868L, G1120R is rare, having been identified once in 2197 genomes (Exome Variant Server
2015).
The third hypomorphic BLM variant that causes elevated SCEs and inefficient DNA break repair, but normal
HU sensitivity and wildtype frequency of quadriradial
chromosomes, is R791C. The affected residue is in the
N-terminal lobe of the ATPase domain in the internal

C

3 loop
(1120GSKSAKIQ1127)

WH

motif II
(785ERKLLARFVIDEAHCV800)

2

-wing

ADP
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-wing

ATPase domain
(C-terminal)
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(C-terminal)
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Figure 6. Location in the crystal structure of human BLM of amino acid changes with intermediate functional impact. (A) P868L maps to a
lysine-rich loop at the periphery of the C-terminal lobe of the ATPase domain. The loop appears to be in contact with dsDNA, which is also
contacted by the WH domain. P868L is at the C-terminal end of a b-strand that transverses lobe 2 of the ATPase domain from the catalytic cleft
to the periphery where DNA is contacted, possibly connecting DNA-substrate binding to ATP-hydrolysis. The crystal structure of BLM in a complex
with ADP and duplex DNA is from PDB (ID: 4O3M). (B) G1120 is located in a loop between the second and third a-helix of the WH-domain that
contacts dsDNA. BLM crystal structure is PDB ID 4O3M. (C) R791 maps to an internal b-strand that precedes the loop of the Walker B motif
involved in Mg2+-binding and ATP hydrolysis. Since the loop in helicase motif II (Walker B) is not resolved in 4O3M (Swan et al. 2014), the R791C
mutation is shown in BLM crystal structure 4CDG (Newman et al. 2013). The amino acid residues changed by the missense mutations are shown
as red spheres. Images were generated with PyMOL v1.3.
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b-sheet that precedes helicase motif II (Walker B)
required for Mg2+ binding and ATP hydrolysis (Fig. 6C).
Hence, the DNA break repair defect of cells expressing
the R791C variant is likely due to diminished ATPase
activity. The allele has been identified once in 97 genomes
from the Han Chinese in Beijing (1000 Genomes Project
Consortium 2012) and twice in 6496 genomes from European-American and African-American populations in the
United States (Exome Variant Server 2015). Although
R791C is so rare it is listed three times in The Cancer
Genome Atlas (TCGA); twice in nonsmall cell lung carcinoma and once in a lymphoid neoplasm (Barretina et al.
2012), raising the possibility that it contributes to
tumorigenesis.
Taken together, we have identified five new BLM missense mutations that exhibit defects of the Bloom syndrome associated blmASH null allele and are therefore new
candidates for Bloom syndrome causing alleles, and three
new BLM missense mutations that exhibit some defects
(elevated interchromatid crossover recombination (SCEs),
slower accumulation and markedly delayed elimination of
cH2AX after genotoxin exposure, and inefficient repair of
replication-dependent DSBs), but not others (HU hypersensitivity, accumulation of quadriradial chromosomes)
(Table 2). H2AX and its phosphorylation at S139 have
been shown to play a role in DSBR by HR between sister
chromatids, which is potentially error-free (Kadyk and
Hartwell 1992; Johnson and Jasin 2000), while preventing
error-prone HR, such as single-strand annealing (SSA)
(Xie et al. 2004). Thus, the severe delay in cH2AX accumulation in cells expressing BLM null alleles (e.g. P690L,
R717T, W803R, Y811C, and G972V in this study), and
the lesser, but significant, delay in cells expressing the
P868L, G1120R, or R791C variants may be indicative of
dysregulation of DSBR, resulting in increased utilization
of SSA or HR between homologs, which are prone to
deletions and LOH respectively. In contrast with H2AX
phosphorylation and its effects on DSBR, the signaling of
cH2AX elimination and the consequences of persistence
of cH2AX, as seen in cells expressing fully or partially
defective BLM variants in this study, are less well-understood, but involves direct dephosphorylation by PP2AB56e (Xie et al. 2004; Chowdhury et al. 2005). Our findings indicate that the requirement of BLM for the accumulation of cH2AX (Rao et al. 2005) extends to its
enzymatic activity, suggesting its requirement for DNA
processing rather than protein binding or recruitment at
DSBs. Our findings further extend the role of BLM’s
enzymatic activity to the elimination of cH2AX. Our
assays cannot distinguish whether BLM is part of the signaling pathway for cH2AX elimination or the effect is
solely through BLM’s role in DSB processing and rejoining, but the severely delayed (>40 h) elimination of
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cellular cH2AX is associated with delayed and, possibly,
error-prone DNA damage repair as well as delays in
restoration of chromatin integrity and the cell cycle.
The functional evaluation of new BLM variants in this
study also provides insight into the in silico predictability
of the impact of SNPs on BLM function (Table 1). Initially we used Polyphen (Ramensky et al. 2002) to rank
43 coding SNPs in BLM, with 22 scoring as either probably or possibly damaging. All eight SNPs that are functionally impaired in yeast and in human cells were
predicted to be ‘probably damaging’ (score > 2). However, Polyphen was unable to distinguish between the null
alleles and the intermediate/hypomorphic alleles. Its successor, PolyPhen2 (Adzhubei et al. 2010), had enhanced
predictability, classifying P868L as an intermediate (possibly damaging) allele. In contrast, both SIFT (Kumar et al.
2009) and FIS (Reva et al. 2011) categorized R717T as
being ‘tolerated’ or of ‘low’ impact respectively. Thus, for
our limited set of variants, this comparison suggests that
for the evolutionarily conserved and highly structured catalytic core of BLM, Polyphen2 was the most accurate predictor of functional impact.
The biological relevance of the functional defects of the
new class of intermediate BLM variants for human health
and aging is currently unclear, as is their importance for
a person’s sensitivity to genotoxins. Although all defects
caused by hypomorphic BLM variants were significantly
less pronounced than in Bloom syndrome cells, any
increased mutation load over a person’s lifetime is likely
to be associated with increased cancer risk; this risk is
known to be extraordinarily high for BLM null alleles,
leading to Bloom syndrome, and now remains to be
defined for the newly identified class of hypomorphic
BLM variants, currently represented by R791C, P868L,
and G1120R.
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Additional Supporting Information may be found in the
online version of this article:
Figure S1. Representative examples of the response of
Bloom syndrome cells (GM08505) expressing wildtype
BLM and BLM variants to replication-dependent DNA
breaks induced by exposure to 1 lmol/L CPT for 1 h.
Figure S2. Effect of PP2A inhibition on cH2AX accumulation in Bloom syndrome cells expressing wildtype BLM
and hypomorphic BLM variants.
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